Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide (marketed as Wegovy and Ozempic) and tirzepatide (Zepbound and Mounjaro) have quickly become cornerstones in the treatment of obesity and type 2 diabetes
We will further look into this and explore how we can help patients with addiction, potentially with GLP-1, Lange said, also adding that it has to be addressed in a scientific, and obviously also from a regulatory perspective, very rigorous way so we can really see the potential impact of GLP-1 in that space. However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to the already ongoing work studying semaglutide on liver damage and alcohol use in its phase 2 trial, and that the company has no plans to study the drug in broader addiction indications
Linus Pauling Institute Oregon State University Updated in January 2014 by: Barbara Delage, Ph.D
McFarthing, K
The weight loss drug industry isnt slowing down
Some clients notice a brighter or more even skin tone after consistent Glutathione therapy